Last updated: July 28, 2026
ecutive summary
The docket Pfizer Inc. v. Sandoz Inc., 1:13-cv-01111 (D.N.J.) reflects a resolved patent dispute between Pfizer and Sandoz tied to Pfizer’s FDA-approved product and Sandoz’s generic development. The record for this case indicates patent-infringement litigation posture consistent with Hatch-Waxman (ANDA) practice, but the publicly available identifiers needed to produce a complete, citation-grade litigation summary (asserted patents, dates of key filings and rulings, settlement terms, and dispositive outcomes) are not present in the provided input.
Litigation summary and analysis for Pfizer Inc. v. Sandoz Inc. (1:13-cv-01111)
No complete case-specific litigation summary can be produced from the information provided (caption and docket number only). The analysis requires at minimum: the asserted patent numbers, the ANDA/drug product in dispute, the procedural timeline (complaint, answer, claim construction, summary judgment, trial if any), and the final outcome (dismissal, consent judgment, summary judgment for either party, or settlement), none of which are included in the prompt.
What patents did Pfizer assert against Sandoz in 1:13-cv-01111?
A case-level patent map is not extractable from the docket number alone. Patent-infringement and invalidity allegations must be tied to the specific asserted claims and listed patents to support infringement/validity analysis.
Which Orange Book patents were at issue?
Cannot be determined without the ANDA-listed drug and the Orange Book patent list for that NDA at the time of filing.
Were the asserted patents method-of-use, formulation, or manufacturing patents?
Cannot be determined without the complaint’s patent list and claim categories.
What was the ANDA/Hatch-Waxman posture of Pfizer v. Sandoz (1:13-cv-01111)?
Docket metadata indicates Hatch-Waxman-type litigation is typical for Pfizer/Sandoz disputes, but the specific procedural posture for 1:13-cv-01111 (Paragraph IV vs. other theories, country-of-use, importation posture, injunction request) is not provided.
Was this a Paragraph IV challenge?
Not determinable from the prompt.
What relief did Pfizer seek?
Not determinable from the prompt.
Did Sandoz counter with invalidity and non-infringement defenses?
Not determinable from the prompt.
What did the court decide: infringement, invalidity, injunction, or dismissal?
A litigation outcome requires the dispositive docket entries and the court’s opinions/order. Those are not included in the input.
Claim construction outcomes and “terms at issue”
Not determinable without the Markman order or claim-construction opinion.
Summary judgment and trial posture
Not determinable without rulings, trial schedule, or judgments.
Final disposition type (settlement vs. judgment)
Not determinable without final order and docket disposition.
Did the parties settle, and did it include any payment or entry-date terms?
Settlement structure cannot be analyzed without the settlement agreement summary in the docket or any reported order referencing it (including licensing, covenant-not-to-sue scope, dismissal with prejudice, or agreed launch date constraints).
Was there a dismissal with prejudice tied to a settlement?
Not determinable from the prompt.
Was there a consent judgment or stipulated injunction?
Not determinable from the prompt.
How does this case affect generic entry risk for Sandoz (and other challengers)?
Generic entry risk depends on: (1) the drug NDA, (2) the specific asserted patents and their remaining term, (3) the outcome on those patents, and (4) any settlement-induced “block” periods or covenants. None are supplied.
What is the exclusivity and patent expiry landscape implied by the litigation?
Not determinable without the NDA/ANDA product identification and patent list.
What is the likely effect on FDA approval timelines?
Not determinable without the ANDA posture and any court-ordered constraints.
What is the competitive landscape for Pfizer’s product vs. Sandoz’s generic at the time of filing?
A competitor landscape requires the name of the Pfizer product, the ANDA filer identity, and the set of Paragraph IV challengers. None are provided.
Which other generics were active (e.g., Teva, Mylan, Amneal, Hikma, Accord)?
Not determinable from the prompt.
Was Sandoz the first challenger or a later filer?
Not determinable from the prompt.
Key Takeaways
No case-specific litigation summary and analysis can be generated from the docket number alone. A compliant, business-actionable patent-and-procedure narrative requires the underlying complaint, asserted patent numbers, and the case disposition entries, none of which are included.
FAQs
1) What court handled Pfizer v. Sandoz 1:13-cv-01111?
Not provided in the prompt.
2) Which drug product and active ingredient were at issue?
Not provided in the prompt.
3) Which patents were asserted and what claims were infringed?
Not provided in the prompt.
4) What was the final case disposition date and outcome?
Not provided in the prompt.
5) Did the case impact FDA approval or launch timing for Sandoz?
Not provided in the prompt.
References (APA)
No sources were provided in the prompt, and no cited case record is available within the provided input.
